Scarica l'app Stockscreener
1.89
33.10%
0.47
Dopo l'orario di chiusura:
1.85
-0.04
-2.12%
Precedente Chiudi:
$1.42
Aprire:
$1.4
Volume 24 ore:
12.94M
Relative Volume:
11.65
Capitalizzazione di mercato:
$112.85M
Reddito:
-
Utile/perdita netta:
$-44.80M
Rapporto P/E:
-2.52
EPS:
-0.75
Flusso di cassa netto:
$-30.67M
1 W Prestazione:
-71.66%
1M Prestazione:
-69.37%
6M Prestazione:
-64.61%
1 anno Prestazione:
-59.66%
Intervallo 1D:
$1.38
$2.00
Intervallo di 1 settimana:
$1.14
$6.55
Portata 52W:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Nome
Aldeyra Therapeutics Inc
Settore
Industria
Telefono
781-761-4904
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Confronta ALDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.89 | 112.85M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-04-27 | Ripresa | H.C. Wainwright | Buy |
| 2021-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-10-30 | Iniziato | Jefferies | Buy |
| 2020-10-16 | Iniziato | BTIG Research | Buy |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Outperform |
| 2018-12-04 | Iniziato | Citigroup | Buy |
| 2018-09-26 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Janney | Buy |
| 2018-01-26 | Iniziato | Seaport Global Securities | Buy |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-01 | Iniziato | Stifel | Buy |
| 2015-07-01 | Iniziato | Canaccord Genuity | Buy |
| 2015-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2015-03-20 | Reiterato | H.C. Wainwright | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2014-06-19 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRL - insights.citeline.com
Laidlaw maintains Buy on Aldeyra, sees upside despite FDA setback - Investing.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aldeyra vows to go ahead after fresh reproxalap setback - The Pharma Letter
INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC - GlobeNewswire
INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - markets.businessinsider.com
Jefferies cuts Aldeyra stock target to $6, maintains Buy rating - Investing.com India
Aldeyra Shares Crash as Dry Eye Drug Gets Second Rejection from FDA - BioSpace
H.C. Wainwright maintains Buy on Aldeyra stock, target at $10 - Investing.com India
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Developments and Robust Financial Health - TipRanks
ADLX STOCK ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - markets.businessinsider.com
Aldeyra Therapeutics Receives FDA Complete Response Letter - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX - TradingView
Reproxalap rapped again in DED; second Aldeyra CRL - BioWorld MedTech
Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter - MSN
Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat - Finimize
Top Midday Decliners - MarketScreener
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Sta - Asianet Newsable
US FDA declines to approve Aldeyra's eye disease drug - Reuters
Crude Oil Dips 7%; ISM Services PMI Falls In March - Benzinga
ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock - GlobeNewswire
Small cap wrap: Excellon Resources, Trust Stamp, Aldeyra Therapeutics... - Proactive Investors
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud ... - Bluefield Daily Telegraph
BREAKING: Block & Leviton Investigating Aldeyra - GlobeNewswire
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the Firm - TradingView
Aldeyra Therapeutics tanks as FDA rejects investigational dry eye disease therapy - Proactive financial news
U.S. FDA declines to approve Aldeyra’s eye disease drug - PharmaLive
US FDA declines to approve Aldeyra’s eye disease drug - The Mighty 790 KFGO
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic - MSN
Aldeyra tumbles as FDA snubs dry eye disease therapy - MSN
FDA issues Complete Response Letter to Aldeyra Therapeutics for resubmitted New Drug Application of reproxalap - Optometry Times
Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall - Benzinga
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns - Benzinga
Aldeyra Therapeutics Gets US FDA Letter for Resubmission of New Drug Application for Eye Disease TreatmentShares Slump Pre-Bell - MarketScreener
Aldeyra Therapeutics stock tumbles after FDA setback By Investing.com - Investing.com South Africa
Aldeyra Therapeutics stock tumbles after FDA setback - Investing.com India
Aldeyra Therapeutics (ALDX) Plummets 74% After FDA Rejection - GuruFocus
Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery - Fierce Biotech
Aldeyra stock tumbles as FDA snubs lead drug (ALDX:NASDAQ) - Seeking Alpha
Aldeyra Therapeutics sets sights on mid-2025 for NDA resubmission - Investing.com
Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease - MarketScreener
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
FDA Denial Forces Aldeyra Back to Trials: Key Details on $101M Cash Position and 2025 Resubmission Plan - Stock Titan
Does Candel Therapeutics Inc (NASDAQ: CADL) Still Need To Convince Analysts? - Stocks Register
Does QXO Inc (NYSE: QXO) Still Look Hot This Week? - Stocks Register
FDA Action Alert: Amgen, Aldeyra and Argenx - BioSpace
Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):